Golden Green’s AstraZeneca AZN Stock Holding History

Golden Green’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,353	Closed	-$435K	–	173
2020 Q4	$435K	Buy	+4,353	New	+$461K	0.4%	69

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Golden Green's AZN Position: Q1 2021 in Review

Golden Green sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 4,353 shares — an estimated $435K sold.

Golden Green first reported a position in AZN in Q4 2020 and held it in 1 quarter. The position peaked at $435K in Q4 2020. 755 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

Golden Green reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
Golden Green sold 4,353 AstraZeneca shares in Q1 2021, an estimated $435K.
Golden Green first reported a position in AstraZeneca in Q4 2020 and held it in 1 quarter.
Golden Green's AstraZeneca position peaked at $435K in Q4 2020.
755 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Golden Green's 13F filing for Q1 2021, filed 13 Apr 2021.